Production of SIV-F/HN: a new Lentivirus vector for CF gene therapy

Production of SIV-F/HN: a new Lentivirus vector for CF gene therapy

Detalles Bibliográficos
Main Authors:	Hyde, S, Alton, E, Boyd, A, Davies, JC, Davies, LA, Gill, DR, Griesenbach, U, Hasegawa, M, Inoue, M, Pringle, IA, Sumner-Jones, SG
Formato:	Conference item
Idioma:	English
Publicado:	Wiley 2015

Títulos similares

ASSESSMENT OF F/HN-PSEUDOTYPED LENTIVIRUS IN A CLINICALLY RELEVANT VECTOR FOR LUNG GENE THERAPY
por: Griesenbach, U, et al.
Publicado: (2012)

Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy.
por: Griesenbach, U, et al.
Publicado: (2012)

ASSESSMENT OF F/HN-PSEUDOTYPED LENTIVIRUS AS A CLINICALLY RELEVANT VECTOR FOR LUNG GENE THERAPY
por: Griesenbach, U, et al.
Publicado: (2012)

Preparation for a first-in-man lentivirus trial in cystic fibrosis patients
por: Griesenbach, U, et al.
Publicado: (2016)

Towards a first-in-human trial with a pseudotyped lentivirus
por: Alton, EW, et al.
Publicado: (2020)

Pre-existing immunity to human parainfluenza virus (hPIV) does not affect rSIV.F/HN-mediated transduction efficiency
por: Pytel, K, et al.
Publicado: (2016)

Assessment of the air-liquid interface culture model as a tool to validate efficacy of a rSIV.F/HN-CFTR vector
por: Sergijenko, A, et al.
Publicado: (2021)

Rapid determination of rSIV.F/HN lentiviral vector titre
por: Conway, CC, et al.
Publicado: (2020)

Expression profile of optimised SIV vector in the mouse lung at early timepoints post-delivery
por: Pringle, I, et al.
Publicado: (2018)

Large-scale, high-throughput production of rSIV.F/HN vectors
por: Viegas, MFA, et al.
Publicado: (2020)

DEVELOPMENT, PRODUCTION AND EVALUATION OF CLINICAL GRADE CFTR EXPRESSION PLASMID FOR CF LUNG GENE THERAPY
por: Gill, DR, et al.
Publicado: (2010)

Low levels of CFTR gene transfer with F/HN pseudotyped lentivirus are sufficient to generate ion transport correction in airway cell cultures from cystic fibrosis patients
por: Sergijenko, A, et al.
Publicado: (2020)

Genetic medicines for CF: Hype versus reality
por: Alton, E, et al.
Publicado: (2016)

EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CF: THE UK CF GENE THERAPY CONSORTIUM "PILOT STUDY"
por: Davies, J, et al.
Publicado: (2009)

Expression profile of optimised SIV vector in the mouse lung at early timepoints post-delivery
por: Pringle, I, et al.
Publicado: (2018)

Improving the quantification of rSIV.F/HN vectors for cystic fibrosis gene therapy using droplet digital PCR
por: Gamlen, T, et al.
Publicado: (2020)

Assessment of selected media supplements to improve F/HN lentiviral vector production yields
por: Gélinas, J, et al.
Publicado: (2017)

Lentivirus gene therapy for autoimmune pulmonary alveolar proteinosis
por: Palau, H, et al.
Publicado: (2019)

Lentivirus GM-CSF gene therapy for autoimmune pulmonary alveolar proteinosis
por: Lund-Palau, H, et al.
Publicado: (2018)

SAFETY AND EXPRESSION OF A SINGLE DOSE OF LIPID-MEDIATED CFTR GENE THERAPY TO THE UPPER AND LOWER AIRWAYS OF PATIENTS WITH CF
por: Davies, J, et al.
Publicado: (2011)

Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis.
por: Alton, E, et al.
Publicado: (2016)

Update on the UK CF Gene Therapy Consortium Multidoes, non-viral, gene therapy trial
por: Alton, E, et al.
Publicado: (2012)

UPDATE ON THE UK CF GENE THERAPY CONSORTIUM MULTIDOSE, NON-VIRAL, GENE THERAPY TRIAL
por: Alton, E, et al.
Publicado: (2012)

UPDATE ON THE UK CF GENE THERAPY CONSORTIUM MULTIDOSE, NON-VIRAL, GENE THERAPY TRIAL
por: Alton, E, et al.
Publicado: (2012)

EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CYSTIC FIBROSIS: THE UK CF GENE THERAPY CONSORTIUM "PILOT STUDY''
por: Davies, J, et al.
Publicado: (2009)

Lentivirus GM-CSF gene therapy ameliorates autoimmune pulmonary alveolar proteinosis
por: Lund-Palau, H, et al.
Publicado: (2018)

OPTIMISATION OF MOLECULAR ASSAYS FOR CLINICAL TRIAL OF GL67A/PDNA DELIVERY TO NOSE AND LUNG OF CF PATIENTS
por: Sumner-Jones, S, et al.
Publicado: (2009)

A PHASE 2B DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF NON-VIRAL MEDIATED GENE THERAPY FOR CF
por: Alton, E, et al.
Publicado: (2013)

Moving lentiviral-based gene therapy into a first-in-man CF trial
por: Griesenbach, D, et al.
Publicado: (2015)

TOXICOLOGY STUDIES IN SUPPORT OF THE UK CF GENE THERAPY CONSORTIUM'S MULTI-DOSE CLINICAL TRIAL
por: Griesenbach, U, et al.
Publicado: (2011)

UKCF gene therapy consortium tracking study: Sputum and serum calprotectin are useful novel measurements in CF exacerbation
por: Gray, R, et al.
Publicado: (2007)

Gene therapy for respiratory diseases; progress and a changing context
por: Alton, EWFW, et al.
Publicado: (2020)

REPEAT ADMINISTRATION OF GL67A/PGM169 IS FEASIBLE, SAFE, AND PRODUCES ENDOGENOUS LEVELS OF CFTR EXPRESSION AFTER 12 DOSES
por: Alton, E, et al.
Publicado: (2012)

Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung.
por: Alton, E, et al.
Publicado: (2014)

Cumulative CFTR expression following repeated aerosol delivery of non-viral pGM169/GL67A formulation to mouse lung
por: Alton, E, et al.
Publicado: (2012)

Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung
por: Alton, E, et al.
Publicado: (2014)

EXERCISE CAPACITY AND PHYSICAL ACTIVITY IN PATIENTS WITH CF: DATA FROM THE UK CF GENE THERAPY CONSORTIUM (UKCFGTC) 'RUN-IN' STUDY
por: Saunders, C, et al.
Publicado: (2010)

3-STEP TAQMAN RT-PCR: ULTIMATE MESSENGER RNA DETECTION SENSITIVITY FOR CF GENE THERAPY CLINICAL TRIALS
por: McCormick, D, et al.
Publicado: (2009)

High levels of native eGFP detected following F/HN lentiviral vector transduction of a variety of lung models
por: Munday, R, et al.
Publicado: (2019)

Delivery of genes into the CF airway
por: Gill, D, et al.
Publicado: (2014)